Home » IDSA » Page 2

Tag Archives: IDSA

Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

Posted on by — No Comments ↓

Sometimes one comes across a particularly well-written policy document which summarizes the status quo of antimicrobial resistance by connecting and synthesizing data from all kinds of sources into a coherent framework. The 2015 OECD Report on Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options for Action Continue reading Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action→

New Treatment Guidelines for Candidiasis – A Major Document to Study

Posted on by — No Comments ↓

In a much-quoted analysis, Lee found that most IDSA Guidelines were supported only by Level III quality data, the lowest category of evidence-based support[1]. The article concludes that more well-designed trials were needed, and clinical judgement should ultimately guide patient management. This all sounds fine and good, and the new Continue reading New Treatment Guidelines for Candidiasis – A Major Document to Study→

The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?

Posted on by — No Comments ↓

Any FDA meeting is a high-stakes game for industry:  One never knows how the discussions will go. Some oddball issue may take center stage and usurp much time, creating an unbalanced perspective.  At other times, simple issues seem to create controversy, questions are not properly understood in the context of Continue reading The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?→